Estudios en fase III del edoxabán

Edoxaban has been studied extensively in phase-III trials, for example, for nonvalvular atrial fibrillation (the ENGAGE AF-TIMI 48 study), for the prevention of recurrent venous thromboembolism (the Hokusai-VTE study) and for the prevention of thromboembolism after orthopedic surgery (the STARS study). In addition, a number of recently published, subanalyses of pivotal trials deserve consideration: these concern different subtypes of stroke and peripheral embolism in patients receiving amiodarone and the treatment of elderly patients.